市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | INmune Bio Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.69 |
|
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 24.61% |
| 机构持股比例 | 27.95% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Raymond James Financial Inc | 30 Jun 2026 | 212,995 |
| Westside Investment Management, Inc. | 30 Jun 2026 | 108,300 |
该时间范围内无数据。
该时间范围内无数据。
投资组合